[go: up one dir, main page]

IL115584A - Replication defective adenoviral vectors with low immunogenicity capable of prolonged expression of a coding sequence comprised therein - Google Patents

Replication defective adenoviral vectors with low immunogenicity capable of prolonged expression of a coding sequence comprised therein

Info

Publication number
IL115584A
IL115584A IL11558495A IL11558495A IL115584A IL 115584 A IL115584 A IL 115584A IL 11558495 A IL11558495 A IL 11558495A IL 11558495 A IL11558495 A IL 11558495A IL 115584 A IL115584 A IL 115584A
Authority
IL
Israel
Prior art keywords
coding sequence
adenoviral vectors
replication defective
low immunogenicity
sequence comprised
Prior art date
Application number
IL11558495A
Other languages
English (en)
Other versions
IL115584A0 (en
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of IL115584A0 publication Critical patent/IL115584A0/xx
Publication of IL115584A publication Critical patent/IL115584A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL11558495A 1994-10-17 1995-10-12 Replication defective adenoviral vectors with low immunogenicity capable of prolonged expression of a coding sequence comprised therein IL115584A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9412346A FR2725726B1 (fr) 1994-10-17 1994-10-17 Vecteurs viraux et utilisation en therapie genique

Publications (2)

Publication Number Publication Date
IL115584A0 IL115584A0 (en) 1996-01-19
IL115584A true IL115584A (en) 2005-11-20

Family

ID=9467911

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11558495A IL115584A (en) 1994-10-17 1995-10-12 Replication defective adenoviral vectors with low immunogenicity capable of prolonged expression of a coding sequence comprised therein

Country Status (11)

Country Link
US (1) US6669942B2 (xx)
EP (1) EP0787198A1 (xx)
JP (1) JP3816952B2 (xx)
AU (1) AU712243B2 (xx)
CA (1) CA2201399A1 (xx)
FI (1) FI971613A7 (xx)
FR (1) FR2725726B1 (xx)
IL (1) IL115584A (xx)
NO (1) NO971590D0 (xx)
WO (1) WO1996012030A1 (xx)
ZA (1) ZA958686B (xx)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024267A1 (en) * 1993-04-20 1994-10-27 Robinson, William, S. Methods and materials for treatment of individuals infected with intracellular infectious agents
PT811073E (pt) * 1995-02-24 2007-03-30 Univ Pennsylvania Utilização de moduladores imunitários para preparar medicamentos que inibem as respostas imunitárias contra vírus recombinantes co-administrados
US6372208B1 (en) 1999-09-28 2002-04-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
US6251957B1 (en) 1995-02-24 2001-06-26 Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
WO1997000326A1 (en) * 1995-06-15 1997-01-03 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
AUPN477695A0 (en) * 1995-08-14 1995-09-07 Commonwealth Scientific And Industrial Research Organisation Gene therapy
WO1998000166A1 (en) * 1996-07-03 1998-01-08 Merial, Inc. Recombinant canine adenovirus (cav) containing exogenous dna
WO1998010087A1 (en) * 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
EP1025242A1 (en) 1997-10-30 2000-08-09 Cornell Research Foundation, Inc. A method of inhibiting an immune response to a recombinant vector
US20040043489A1 (en) * 1998-07-08 2004-03-04 Menzo Havenga Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6451319B1 (en) 1999-04-09 2002-09-17 Schering-Plough Veterinary Corporation Recombinant and mutant adenoviruses
WO2000061773A1 (en) * 1999-04-09 2000-10-19 Schering-Plough Ltd. Recombinant and mutant adenoviruses derived of bovine adenovirus type 1
ATE364707T1 (de) * 1999-05-17 2007-07-15 Crucell Holland Bv Rekombinanter humaner adenovirus-serotyp 35
US6913922B1 (en) * 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US20050232900A1 (en) * 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
GB9924981D0 (en) 1999-10-21 1999-12-22 Univ Manchester Gene therapy
CN1254719A (zh) * 1999-11-19 2000-05-31 钱其军 一种缺陷型腺病毒及其构建方法
EP1157999A1 (en) * 2000-05-24 2001-11-28 Introgene B.V. Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof
EP1322774A2 (en) * 2000-09-20 2003-07-02 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for dendritic cells
DE60138403D1 (de) 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
EP1203819A3 (en) * 2000-10-06 2002-08-07 Transgene S.A. Anti-inflammatory vectors
KR100432953B1 (ko) * 2001-09-01 2004-05-28 김주항 개선된 종양 살상 효과를 나타내는 재조합 아데노바이러스
CN100497639C (zh) 2002-04-25 2009-06-10 克鲁塞尔荷兰公司 生产腺病毒载体的手段和方法
ATE511401T1 (de) 2004-08-12 2011-06-15 Cedars Sinai Medical Center Kombinierte gentherapie zur behandlung makroskopischer glioma
WO2007086879A2 (en) 2005-02-11 2007-08-02 University Of Southern California Method of expressing proteins with disulfide bridges
US20060286074A1 (en) * 2005-05-31 2006-12-21 Yucheng Tang Methods for immunotherapy of cancer
AU2006311752A1 (en) * 2005-11-07 2007-05-18 Sidney Kimmel Cancer Center CD40 ligand fusion protein vaccine
WO2008095027A2 (en) 2007-01-30 2008-08-07 Cedars-Sinai Medical Center Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene
WO2010056901A2 (en) 2008-11-13 2010-05-20 University Of Southern California Method of expressing proteins with disulfide bridges with enhanced yields and activity
US10837020B2 (en) * 2009-04-22 2020-11-17 Massachusetts Institute Of Technology Innate immune suppression enables repeated delivery of long RNA molecules
EP2421563B1 (en) 2009-04-22 2017-04-12 Massachusetts Institute of Technology Innate immune suppression enables repeated delivery of long rna molecules
WO2012125791A2 (en) * 2011-03-17 2012-09-20 Xiaoliu Zhang Incorporation of the b18r gene to enhance antitumor effect of virotherapy
US8445781B1 (en) 2011-11-15 2013-05-21 Nova D. Chasser Electrical receptacle cover having safety bracket for use with fragrance dispenser
TW201823465A (zh) 2016-09-20 2018-07-01 德商百靈佳殷格翰維美迪加股份有限公司 新穎豬流感疫苗
CN109715204B (zh) 2016-09-20 2023-08-22 勃林格殷格翰动物保健有限公司 新的ehv插入位点orf70
EA201990718A1 (ru) 2016-09-20 2019-10-31 Векторы аденовируса собачьих
DK3516064T3 (da) 2016-09-20 2025-07-14 Boehringer Ingelheim Vetmedica Gmbh Nye promotorer
US11839655B2 (en) 2017-09-01 2023-12-12 Microvax, Llc Combination cancer therapy
EP4221738A1 (en) 2020-09-30 2023-08-09 Alma Bio Therapeutics Nucleic acid therapy for differential modulation of host microflora

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1216710B1 (en) * 1991-10-04 2006-04-05 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
WO1994004196A1 (en) * 1992-08-14 1994-03-03 Imperial Cancer Research Technology Limited Tumour therapy
WO1994012649A2 (en) * 1992-12-03 1994-06-09 Genzyme Corporation Gene therapy for cystic fibrosis
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.

Also Published As

Publication number Publication date
NO971590L (no) 1997-04-07
US6669942B2 (en) 2003-12-30
US20020006395A1 (en) 2002-01-17
AU712243B2 (en) 1999-11-04
FI971613L (fi) 1997-04-16
AU3658495A (en) 1996-05-06
NO971590D0 (no) 1997-04-07
CA2201399A1 (fr) 1996-04-25
WO1996012030A1 (fr) 1996-04-25
JPH10507079A (ja) 1998-07-14
FI971613A0 (fi) 1997-04-16
IL115584A0 (en) 1996-01-19
FI971613A7 (fi) 1997-04-16
FR2725726B1 (fr) 1997-01-03
ZA958686B (en) 1996-05-22
JP3816952B2 (ja) 2006-08-30
EP0787198A1 (fr) 1997-08-06
FR2725726A1 (fr) 1996-04-19

Similar Documents

Publication Publication Date Title
IL115584A (en) Replication defective adenoviral vectors with low immunogenicity capable of prolonged expression of a coding sequence comprised therein
US5567115A (en) Flashlight with flexible core
SG47466A1 (en) Reed-solomon decoder
GB9326574D0 (en) Dry power inhalers
IL108169A0 (en) New peptides
EP0765165A4 (en) PREVENTED PEPTIDES
AU682128B2 (en) Vector encoding method and encoder/decoder using the method
AU120682S (en) Chair shell
AU121250S (en) Chair
HU9400750D0 (en) Armchair
SG50679A1 (en) Chair
ZA955797B (en) Adenovirus comprising a sequence coding for an NO synthase
GB9425380D0 (en) Peptides
GB9417959D0 (en) Inflatable figure
GB9618890D0 (en) An immunogenic determinant
GB9413751D0 (en) Immunodominant peptides
AU3048689A (en) Immunogenic peptides
PL309806A1 (en) Glue stick with plunger-type stick holder
IL90833A0 (en) Immunogenic peptide
GB2225140B (en) Decoding arrangements
AU121293S (en) Chair
GB9423178D0 (en) Resin formulations
RU1832384C (en) Coding unit
PHUM7799Z (en) Improve armchair
AU123143S (en) An armchair

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees